Catalog4 refs
Semaglutide
MetabolicMetabolic & Weight Lossglp1GLP-1 Receptor Agonist | Weight Loss & DiabetesWeight LossResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing. Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways.
Primary Uses
Weight management
Type 2 diabetes treatment
Appetite suppression
Blood sugar regulation
Cardiovascular protection
Type 2 diabetes
Chronic weight management
Cardiovascular risk reduction
Weight-loss and obesity management
Appetite regulation
Cardiometabolic outcomes
GLP-1 pharmacology research
Appetite and craving control
Sustained weight maintenance
Type 2 diabetes glycemic control
Beta cell preservation
Metabolic syndrome improvement
NASH/fatty liver treatment
Inflammation reduction
CKD / kidney protection
Non-cirrhotic MASH
Protocol Reference
Dose
0.25–2.0 mg weekly
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
Half-life
Approximately 7 Days
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 4, FDA Approved / FDA-approved / FDA Approved (disputed)
Research References· 24
Research Models
HumanMouseRatrodents
Also in Metabolic